CRSP
CRISPR Therapeutics AG
NASDAQ · Healthcare · Biotechnology · CH
$50.04
+1.60%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$49.83
From 52W high−32.35%
Volume1.07M
Market cap$4.84B
P/E (TTM)—
P/S (TTM)361.3x
Div yield—
Key dataOct 19, 2026
Open
$49.83
From 52W high
−32.35%
Volume
1.07M
Market cap
$4.84B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.2x
P/E (TTM)
—
RSI (14)
41.5
MomentumView details →
1D Return
+1.60%
YTD Return
−4.66%
SummaryUpdated Jun 1, 2026
CRISPR Therapeutics AG (NASDAQ:CRSP) is a Swiss-based gene editing company founded in 2013 that develops gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform technology. The company went public in October 2016 and has emerged as one of the leading players in the rapidly evolving field of gene editing therapeutics. CRISPR Therapeutics focuses on creating treatments for conditions ranging from blood disorders to cancer and diabetes, with its lead therapy CTX001 representing one of the first CRISPR-based treatments to advance through clinical trials toward potential regulatory approval.
Similar companies
Latest newsMore news →
CRISPR Therapeutics AG announced that Chief Financial Officer Raju Prasad will step down to pursue external opportunities.9h agoCRISPR Therapeutics AG shares fell 4.48% to $49.21 from the prior session's close.3d agoCRISPR Therapeutics AG shares closed at $51.55, down 3.45% from the prior trading day.7d ago